Abstract
AMPA receptors are the major excitatory neurotransmitter receptors in the central nervous system and are involved in numerous neurological disorders. An agonist-binding site is present in each of four subunits that form a functional channel. Binding consists of three steps: docking of agonist to the bilobed ligand binding domain (LBD), closure of the LBD, and increased stability of the closed-lobe conformation through interlobe hydrogen bonding. We describe GluA3 single channel currents activated by nitrowillardiine (NO2W) and chlorowillardiine (ClW) in the presence of cyclothiazide, in conjunction with crystal structures of GluA2 and GluA3 LBDs bound to fluorowillardiine (FW), ClW, and NO2W. When bound to NO2W or ClW, the GluA3 channel opens to three conductance levels with comparable open probabilities and displays modal behavior similar to that obtained with glutamate and FW as agonists (Poon et al., 2010). At lower concentrations, ClW evoked an alternate kinetic behavior, consisting of high open probability in lower conductance states. The structure of ClW bound to GluA3 LBD exhibits a unique partially open hydrogen bonding structure that may be associated with these alternative kinetics. NO2W evoked longer open times than seen for other agonists in high and very high modes. The structure ofGluA2 LBD bound to NO2W exhibits fully closed lobes with additional interlobe interactions mediated by the nitro group. Beyond differences in efficacy between full and partial agonists, the complexities of the single channel behavior of AMPA receptors may also be associated with small interactions that modify the stability of various degrees of closure.
Footnotes
L.M.N. and R.E.O. were dual Primary Investigators for this work.
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant R01-NS049223] and the National Institutes of Health National Institute of Neurological Disorders and Stroke [Ruth L. Kirschstein National Research Service Award 1F31-NS063518] (to K.P.).
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.111.071688.
-
ABBREVIATIONS:
- AMPA
- α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid
- LBD
- extracellular ligand-binding domain of GluA2 and GluA3
- FW
- (S)-5-fluorowillardiine [(S)-(−)-α-amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)pyridine-propanoic acid]
- NO2W
- (S)-5-nitrowillardiine [(S)-(−)-α-amino-5-nitro-3,4-dihydro-2,4-dioxo-1(2H)pyridine-propanoic acid]
- ClW
- (S)-5-chlorowillardiine [(S)-(−)-α-amino-5-chloro-3,4-dihydro-2,4-dioxo-1(2H)pyridine-propanoic acid]
- VL
- very low
- L
- low
- M
- medium
- H
- high
- VH
- very high
- LL
- log likelihood
- MIL
- maximum interval likelihood
- NMDA
- N-methyl-d-aspartic acid
- Pc
- closed probability
- Po
- open probability
- BrW
- bromowillardiine
- IW
- iodowillardiine.
- Received February 9, 2011.
- Accepted April 4, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|